Asthma Clinical Trial
Official title:
Multicenter, Prospective, Non-interventional, Observational Study on Treatment of Asthma in Children.
Patients' satisfaction with their asthma medication devices is usually decided by using
properly designed questionnaires. These questionnaires are to be used to evaluate patients'
opinion, which is considered very important for the selection of a device.
The Feeling of Satisfaction with Inhaler (FSI-10) is a self-completed questionnaire designed
to assess the patient opinion regarding the satisfaction and usability of the inhalers
irrespectively of the drug used. It consists of 10 question each with 5 possible responses
on a 5-point Likert scale scored from 5 to 1, respectively. The total score can range
between 10 and 50. The higher the score, the higher the feeling of patient satisfaction from
the inhaler.
Childhood and adolescents' asthma is the most common chronic disease of childhood and is the
major cause of absenteeism from school students. To deal with the disease often require
hospitalization, fortunately, very rare enough to be life-threatening. Since the mid-80s had
clearly expressed by several centers to observe the rising incidence of the disease. The
next year observation was confirmed many times. Childhood asthma has been characterized as a
disease of modern Western civilization. It affects a large proportion of the child
population and seems to take longer epidemic character.
From studies carried out recently in Greece found that children of school age asthmatic type
symptoms during the past 12 months appear to 5-10% of pupils. The rates are doubled when the
question is not limited to the last 12 months. Also in a study involving 2133 children aged
7 and 18 years, the prevalence of asthma was 7.7% and 4.7% (at the age of 7 and 18 years
respectively) and chronic asthma 19.6% and 26.3% (at the age of 7 and 18 years,
respectively), while over half of the children (58.2%) with early asthma (asthma diagnosed
before age 7) had no symptoms at the age of 7. At the age of 18 still had symptoms for 7.6%
of children with early asthma and 48.2% of children who developed asthma between 7-18 years
(6.7% of study participants).
For the onset of childhood asthma synergize two factors: genetic, ie heredity, and
environmental, that is the environment in which we live. There is a predisposition for the
disease and the environment favors the onset. So to increase the prevalence implicated: a)
genetic predisposition, b) the method of construction of houses, c) smoking (assets -
liabilities), c) indoor pollution, d) atmospheric pollution, e) the modern way of eating and
clothing and f) preventing illness by a large number of serious infections due to the
widespread use of vaccines.Most asthma medications are administered using suitable inhalers.
There are various types of devices that facilitate the administration of inhaled medications
in young children. The correct use of inhalational devices is very important for the
treatment of asthma. If the patient does not understand the instructions, the drug is
deposited satisfactorily lungs, ie organ must act, so there is no remission.
;
Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|